Market open · Delayed intraday data · 2:24 PM ET
Last update: Nov 20, 2026, 2:02 PM ET
Vertex Pharmaceuticals Incorporated
$519.45▼ 0.23% today
Market Open

Why Vertex Pharmaceuticals Incorporated (VRTX) stock moved

Latest session▼ 2.9% · Nov 19, 2026 close

Why Vertex Pharmaceuticals Incorporated (VRTX) fell 2.9% on November 19, 2026

Vertex Pharmaceuticals Incorporated (VRTX) fell 2.9% on November 19, 2026, closing at $520.66 versus $536.45 the prior session (close-to-close, from daily closes). We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was found. The move appears to be part of a sector-wide decline, with 8 healthcare peers including Amgen (-4.17%), Merck (-7.37%), AbbVie (-3.17%), and Pfizer (-3.27%) moving lower on the same day. Source: FMP price data; BestStocks detection.

Updated
Prior close
$536.45
Nov 19, 2026 close
$520.66
Change (close-to-close)
−$15.79
−2.94%
As first detected · Nov 19, 2026, 4:46 PM ET

Vertex Pharmaceuticals Incorporated (VRTX) moved -3.19% from $537.79 to $520.66 on 2026-11-19. We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was found. The move appears to be part of a sector-wide decline, with 8 healthcare peers including Amgen (-4.17%), Merck (-7.37%), AbbVie (-3.17%), and Pfizer (-3.27%) moving lower on the same day. Volume remained near its 5-day average.

What to watch next: VRTX earnings scheduled for 2026-02-11 (consensus EPS estimate $4.20).

Source: FMP price data; BestStocks detection · percentages in this note are as captured at detection; the confirmed close-to-close move is shown above.

Earlier sessions that moved VRTX

  1. +3.4%Two days prior, VRTX reported Q3 EPS of $4.76 versus a $4.82 estimate (−1.24% miss); Q3 revenue grew 12% YoY to $3.44B, led by cystic fibrosis drugs and new launches CASGEVY and PALSONIFY.
  2. −4.0%Vertex Pharmaceuticals reported Q3 adjusted EPS of $4.76, missing the Zacks consensus estimate of $4.92, according to the web catalyst.
  3. +3.5%We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was found.
  4. +2.5%Vertex appoints Daniel Brennan, 35-year healthcare finance veteran, as independent board director.
  5. −4.3%A Motley Fool comparison (published 2026-10-13) contrasts Vertex's cystic fibrosis dominance and diversification efforts against Moderna's mRNA expansion into RSV and oncology, but this is a retrospective ranking piece rather than a company-specific event.
  6. −3.1%We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was found.

Vertex Pharmaceuticals Incorporated (VRTX) shares fell 0.2% to $519.45 as of November 20, 2026, a slight decline from the prior close of $520.66. BestStocks flagged the session as a major change for VRTX. Below, we break down what changed for VRTX, why it matters for investors, how the stock reacted, and the catalysts on the calendar.

What happened

VRTX fell 0.2% to $519.45

Vertex Pharmaceuticals Incorporated (VRTX) filed its 10-Q on November 3, 2026. VRTX earnings report on February 11, 2027 (date not yet confirmed).

This summary describes the catalyst and move as first detected on Nov 3, 2026, 4:45 PM EST; the stock has continued trading since, so the current price and percentage move (shown above) may be larger or smaller than the figures here.
Company-Specific MoveWeak confidence
Rel. volume
0.5×
Below Avg
Vs peers
Top 7 of 7 peers
Underperforming
Market cap
$131.7B
NASDAQ Global Select
Analyst target
$579
+11.5% vs price
Price chart
Oct 20 – Nov 20
FVNNFF$514$537$560Oct 20Oct 28Nov 5Nov 12Nov 20
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details

What it means for Vertex Pharmaceuticals Incorporated investors

For Vertex Pharmaceuticals Incorporated investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Positive price momentum; Positive price momentum. Weighing against that: Negative session, down 0.2%; Vertex Pharmaceuticals declined 2.09% to $496.42 in early trading with no material catalyst evident in real-time news. Because the move outpaced peers, it looks driven by VRTX-specific developments rather than a broad sector rotation. Wall Street's consensus price target sits at $579.29, implying +11.5% upside from $519.45. BestStocks rates the overall signal quality weak (20/100). With earnings roughly 83 days out, the next report is the most likely near-term test of the move.

VRTX price reaction

VRTX last traded at $519.45, down $1.21 (-0.23%) from the previous close of $520.66. The session traded on 0.5× average volume (below avg), so participation was unremarkable. Its healthcare peer group moved a median +1.8% over the same stretch, leaving VRTX behind the group by 2.0 points. Over the past month the stock has ranged between $514.65 and $558.88, and it currently sits about 11% of the way up that band.

Bullish and bearish analyst opinions on Vertex Pharmaceuticals Incorporated (VRTX)

The consensus analyst price target on Vertex Pharmaceuticals Incorporated (VRTX) is $579.29, 11.5% above the recent $519.45. Over the past 90 days analysts logged 0 upgrades, 13 maintains, and 0 downgrades. Here is how the bullish and bearish cases on VRTX line up.

The bullish case

  • Wall Street's consensus price target of $579.29 implies +11.5% upside from $519.45.
  • The Street's most bullish target is $665.00 (+28.0%).
  • Positive price momentum.

The bearish case

  • The most bearish analyst target is $350.00 (-32.6%).
  • Negative session, down 0.2%.
  • Vertex Pharmaceuticals declined 2.09% to $496.42 in early trading with no material catalyst evident in real-time news.
Bull vs bear balanceNeutral / Mixed
BearishNeutralBullish

Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.

Analyst price targets and ratings are FMP consensus figures as of Nov 20, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.

Analyst expectations
Consensus target: $579+11.5%
= 13 maintains
Barclays maintained Overweight · 2026-11-04
SEC filings watch
10-Q2026-11-03
Quarterly financial results
medium
8-K2026-11-02
Material event — review for impact
high
8-K2026-10-20
Material event — review for impact
high
8-K2026-09-01
Material event — review for impact
high
Peer context
VRTX-0.2%
LLY+0.0%
UNH+3.9%
JNJ+1.8%
PFE+0.2%
ABBV+1.9%

Previous notable changes for VRTX

Valuation2026-11-03-4.0%via Benzinga ↗
Vertex Pharmaceuticals reported Q3 adjusted EPS of $4.76, missing the Zacks consensus estimate of $4.92, according to the web catalyst. Despite revenue beating expectations at $3.44 billion (+12% YoY) and analysts raising forecasts post-earnings (Benzinga), the EPS miss and higher operating/integration costs from the $9.0 billion Crinetics Pharmaceuticals acquisition triggered selling pressure. Stock down 3.10% to $536.02 on elevated volume of 2.81x historical average.
Filings2026-11-02-1.0%
Vertex Pharmaceuticals Incorporated (VRTX) filed a new 8-K on November 2, 2026. The filing content was not disclosed in available records.
News2026-10-23-2.1%
Vertex's Phase 3 RAINIER trial for povetacicept in IgA Nephropathy showed best-in-class potential, published in NEJM.
News2026-10-20+2.5%
Vertex appoints Daniel Brennan, 35-year healthcare finance veteran, as independent board director.
Upcoming catalysts & outlook
Next earnings
2027-02-11 (est.)
in 83 days
Earnings Release
2027-02-11
High impact
Thesis shift
Neutral / Mixed
bearish signal
Risk level
Medium
from change events

Frequently asked questions about VRTX

Why did Vertex Pharmaceuticals Incorporated (VRTX) stock move?

Vertex Pharmaceuticals Incorporated (VRTX) fell 2.9% on November 19, 2026, closing at $520.66 versus $536.45 the prior session (close-to-close, from daily closes). We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was found. The move appears to be part of a sector-wide decline, with 8 healthcare peers including Amgen (-4.17%), Merck (-7.37%), AbbVie (-3.17%), and Pfizer (-3.27%) moving lower on the same day. Source: FMP price data; BestStocks detection.

How much did VRTX stock fall?

VRTX lost 0.23% ($1.21) versus the prior close of $520.66, last trading at $519.45 on 0.5× average volume.

When is Vertex Pharmaceuticals Incorporated's next earnings date?

VRTX's next earnings report is estimated for 2027-02-11 — about 83 days away.

What is the analyst price target for VRTX?

The consensus analyst price target for VRTX is $579.29, about 11.5% above the current $519.45. Over the past 90 days, analysts recorded 0 upgrades, 13 maintains, and 0 downgrades.

Is the VRTX move company-specific or sector-wide?

BestStocks classifies it as a company-specific move: the peer group moved a median +1.8% against VRTX's -0.2%. VRTX ranks top 7 of 7 peers.

How BestStocks tracks VRTX

This page is generated automatically by BestStocks' change-detection system after its price and volume cleared VRTX-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for VRTX, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of November 20, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.

Data sources
FMP real-time & historical price dataSEC EDGAR filingsFMP earnings & estimatesAnalyst ratings & price targets (FMP)Earnings calendar (FMP)
Educational research tool — not personalized investment advice. Data may be delayed.